lomustine - CISMeF

Preferred Label : lomustine;

MeSH definition : An alkylating agent of value against both hematologic malignancies and solid tumors.;

CISMeF synonym : Bristol-Myers squibb brand of lomustine; Rhône-Poulenc rorer brand of lomustine; bristol myers squibb brand of lomustine; lomustine medac brand; medac brand of lomustine; rhône poulenc rorer brand of lomustine;

MeSH hyponym : cecenu; belustine; NSC-79037; CCNU; CeeNU; NSC 79037; NSC79037;

MeSH CAS label : urea, N-(2-chloroethyl)-N'-cyclohexyl-N-nitroso-;

MeSH Related Number : 13010-47-4 (Lomustine);

Registry Number MeSH : 13010-47-4;

Wikipedia link : https://en.wikipedia.org/wiki/Lomustine;

Codes EINECS : 235-859-2;

Is substance : O;

UNII : 7BRF0Z81KG;

InChIKey : GQYIWUVLTXOXAJ-UHFFFAOYSA-N;

Details

Origin ID

D008130;

UMLS CUI

C0023972;

ATC code(s)
- lomustine [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
CISMeF manual mappings
- Lomustine adverse reaction (disorder) [SNOMED CT concept]
- Lomustine poisoning (disorder) [SNOMED CT concept]
- lomustine [Substance BNPC]
Currated CISMeF NLP mapping
- Lomustine [ICD-11 Extension code]
- Lomustine [ICHI extension code]
- Lomustine [SMS substance]
- Lomustine [NCIt concept]
- Lomustine (substance) [SNOMED CT concept]
- lomustine [SNOMED Notion]
Pharmacological action(s)
- antineoplastic agents, alkylating [MeSH Descriptor]
Record concept(s)
- CCNU [MeSH concept]
- CeeNU [MeSH concept]
- NSC-79037 [MeSH concept]
- belustine [MeSH concept]
- cecenu [MeSH concept]
- lomustine [MeSH concept]
Related MeSH Supplementary Concept(s)
- 1-(2-fluoroethyl)-3-cyclohexyl-1-nitrosourea [MeSH Supplementary Concept]
- 2-hydroxylomustine [MeSH Supplementary Concept]
- 4-((((2-chloroethyl)nitrosoamino)carbonyl)methylamino)cyclohexanecarboxylic acid [MeSH Supplementary Concept]
- 4-hydroxylomustine [MeSH Supplementary Concept]
- ABDIC protocol [MeSH Supplementary Concept]
- ACHM protocol [MeSH Supplementary Concept]
- B-CAVe protocol [MeSH Supplementary Concept]
- BACON protocol [MeSH Supplementary Concept]
- BCNYU [MeSH Supplementary Concept]
- BELD protocol [MeSH Supplementary Concept]
- BMC protocol [MeSH Supplementary Concept]
- BOLD protocol [MeSH Supplementary Concept]
- C'MP protocol [MeSH Supplementary Concept]
- CAD protocol 1 [MeSH Supplementary Concept]
- CAD protocol 2 [MeSH Supplementary Concept]
- CAMP combination [MeSH Supplementary Concept]
- CAPE-PALE protocol [MeSH Supplementary Concept]
- CAV regimen [MeSH Supplementary Concept]
- CAVP protocol [MeSH Supplementary Concept]
- CBC protocol [MeSH Supplementary Concept]
- CBVD protocol [MeSH Supplementary Concept]
- CCAVP16 protocol [MeSH Supplementary Concept]
- CCNU-VP protocol [MeSH Supplementary Concept]
- CCOM protocol [MeSH Supplementary Concept]
- CCV protocol [MeSH Supplementary Concept]
- CCV-AV protocol [MeSH Supplementary Concept]
- CCVPP protocol [MeSH Supplementary Concept]
- CEP protocol [MeSH Supplementary Concept]
- CEVD protocol [MeSH Supplementary Concept]
- CMV regimen [MeSH Supplementary Concept]
- COCE protocol [MeSH Supplementary Concept]
- COMB protocol [MeSH Supplementary Concept]
- CONB-A protocol [MeSH Supplementary Concept]
- COPAC protocol [MeSH Supplementary Concept]
- CVPP protocol [MeSH Supplementary Concept]
- DFMO-PCV protocol [MeSH Supplementary Concept]
- FAMe protocol [MeSH Supplementary Concept]
- FCV protocol [MeSH Supplementary Concept]
- LBCMVD-56 protocol [MeSH Supplementary Concept]
- LCOMP protocol [MeSH Supplementary Concept]
- LEAMP protocol [MeSH Supplementary Concept]
- LEMP protocol [MeSH Supplementary Concept]
- LOPP protocol 2 [MeSH Supplementary Concept]
- LTPP protocol [MeSH Supplementary Concept]
- MACC combination [MeSH Supplementary Concept]
- MCC protocol [MeSH Supplementary Concept]
- MCHC protocol [MeSH Supplementary Concept]
- MCM protocol [MeSH Supplementary Concept]
- MOCCA protocol [MeSH Supplementary Concept]
- MOPPEBVCAD protocol [MeSH Supplementary Concept]
- MVC protocol 2 [MeSH Supplementary Concept]
- NSC 153174 [MeSH Supplementary Concept]
- PACET protocol [MeSH Supplementary Concept]
- PCV protocol [MeSH Supplementary Concept]
- POCC protocol [MeSH Supplementary Concept]
- SCAB protocol [MeSH Supplementary Concept]
- SIOP-I protocol [MeSH Supplementary Concept]
- TACC protocol [MeSH Supplementary Concept]
- TPDC-FuHu protocol [MeSH Supplementary Concept]
- TPDCV protocol [MeSH Supplementary Concept]
- VABCD protocol [MeSH Supplementary Concept]
- VCPC protocol [MeSH Supplementary Concept]
- VINAP protocol [MeSH Supplementary Concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Lomustine [ICD-11 Extension code]
- Lomustine [NCIt concept]
- Lomustine (substance) [SNOMED CT concept]
- Product containing lomustine (medicinal product) [SNOMED CT concept]
- lomustine [ATC Code]
- lomustine [Substance BNPC]
- lomustine [SNOMED Notion]
Validated automatic mappings to BTNT
- lomustine [ATC Code]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients